文献速递头颈与中枢神经肿瘤

单细胞网络与机器学习解析复发胶质母细胞瘤铁死亡:星形胶质细胞ZFP36作为网络医学重定位的治疗枢纽

Single-cell systems network and machine learning dissection of ferroptosis in recurrent glioblastoma highlights astrocytic ZFP36 as a therapeutic hub for network medicine repurposing.
PubMed 文献 · Eur J Cancer · 2026-02-17

本研究利用公共单细胞数据集分析复发胶质母细胞瘤(rGBM)与原发GBM(pGBM)中肿瘤特异性胶质细胞的铁死亡相关扰动,通过网络机器学习识别星形胶质细胞中的铁死亡抑制因子ZFP36。网络医学、分子对接和动力学模拟发现4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide可与ZFP36可成药结合位点结合并调节其结构,提示调控ZFP36可通过铁死亡通路促进rGBM细胞死亡。

要点

  • rGBM中星形胶质细胞ZFP36被网络机器学习识别为铁死亡抑制因子。
  • ZFP36相互作用亚网络富集MAPK和代谢通路,支持其促肿瘤生长作用。
  • 4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide可结合ZFP36可成药位点并调节其结构。

核心结论

  • 调控铁死亡抑制因子ZFP36可能通过铁死亡通路促进复发胶质母细胞瘤细胞死亡。

研究设计与样本

  • 研究基于公共单细胞数据集分析rGBM与pGBM的肿瘤特异性胶质细胞及铁死亡相关扰动。
  • 采用基于网络的机器学习分析识别rGBM关键铁死亡驱动因子。
  • 运用网络医学、分子对接和分子动力学模拟鉴定潜在治疗靶点。

主要发现

  • 基于网络的排序在星形胶质细胞中捕获铁死亡抑制因子ZFP36。
  • ZFP36相互作用亚网络的通路富集分析显示MAPK和代谢通路,支持其在肿瘤生长中的作用。
  • 网络医学 proximity 分析显示药物结合的MAP激酶更接近ZFP36,提示这些药物可能调节ZFP36活性。
  • 与已知铁死亡诱导剂的相似性分析识别4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide为ZFP36的潜在药物靶点。
  • 分子对接和动力学模拟显示该药物结合ZFP36可成药结合位点并调节其结构。

临床怎么用

  • ZFP36可作为rGBM铁死亡相关网络医学药物重定位的候选治疗枢纽。
  • 4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide为靶向ZFP36的潜在药物,需进一步实验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent glioblastoma multiforme (rGBM) arises after conventional treatment strategies for primary GBM (pGBM) fail, leading to a more aggressive, therapy-resistant phenotype, with an overall survival of ∼9 months. Current treatment strategies rely on apoptosis and are frequently ineffective. Moreover, ferroptosis has recently been identified as a potential alternative cell death pathway in glioma. Therefore, this study investigated the mechanisms and therapeutic potential of ferroptosis in rGBM at the glial cell type level. METHODS: We analyzed a publicly available single-cell datasets to profile tumor-specific glial cells and assess ferroptosis-related perturbations in rGBM versus pGBM. Network-based machine learning analyses were employed to highlight key ferroptosis drivers in rGBM. Finally, we employed network medicine, molecular docking, and molecular dynamics simulations to identify a potential therapeutic target. RESULTS: Network-based ranking captured a ferroptosis suppressor, ZFP36, in astrocytes, and pathway enrichment analysis of its interaction subnetwork revealed MAPK and metabolic pathways, supporting its role in tumor growth. Network medicine identified drugs targeting ZFP36, with proximity analysis showing that drug-binding MAP kinases are closer to ZFP36, suggesting that these drugs may also modulate ZFP36 activity. Furthermore, similarity analyses with known ferroptosis inducers identified 4-Phenoxy-N-(Pyridin-2-Ylmethyl)Benzamide as a potential drug target for ZFP36. Molecular docking and dynamics simulations showed that the drug binds to the druggable binding site of ZFP36, modulating its structure. CONCLUSION: The findings of this study suggest that modulating ferroptosis suppressor ZFP36 could promote cell death in rGBM via the ferroptosis pathway.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kishinani M, Girish M, Sinha S, et al. Single-cell systems network and machine learning dissection of ferroptosis in recurrent glioblastoma highlights astrocytic ZFP36 as a therapeutic hub for network medicine repurposing. Eur J Cancer. 2026. PMID: 41713080. doi:10.1016/j.ejca.2026.116591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。